Hanna Vasarainen1, Jolanda Salman2, Heidi Salminen3, Riccardo Valdagni4, Tom Pickles5, Chris Bangma2, Monique J Roobol2, Antti Rannikko3. 1. Department of Urology, Peijas Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 900, 00029, Helsinki, Finland. hanna.vasarainen@hus.fi. 2. Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands. 3. Department of Urology, Peijas Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 900, 00029, Helsinki, Finland. 4. Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Department of Radiation Oncology and Developmental Radiotherapeutics, University of British Columbia, and BC Cancer Agency, Vancouver, Canada.
Abstract
PURPOSE: To evaluate the utility of percentage of free serum PSA (%fPSA) as a predictor of adverse rebiopsy findings, treatment change and radical prostatectomy (RP) findings in a prospective active surveillance (AS) trial. METHODS: Patients enrolled in the global PRIAS study with baseline %fPSA available were included. Putative baseline predictors (e.g. PSA, %fPSA) of adverse rebiopsy findings were explored using logistic regression analysis. Association of variables with treatment change and RP findings over time were evaluated with Cox regression analysis. Active treatment-free survival was assessed with a Kaplan-Meier method. RESULTS: Of 3701 patients recruited to PRIAS, 939 had %fPSA measured at study entry. Four hundred and thirty-eight of them had %fPSA available after 1 year. Median follow-up was 17.2 months. First rebiopsy results were available for 595 patients and of those, 144 (24.2 %) had adverse findings. A total of 283 (30.1 %) patients discontinued surveillance, of those 181 (64.0 %) due to protocol-based reasons. Although median %fPSA values were significantly lower in patients who changed treatment, according to the multivariate regression analysis, initial %fPSA value was not predictive for treatment change or adverse rebiopsy findings. However, the probability of discontinuing AS was significantly lower in patients with "favourable" initial %fPSA characteristics and %fPSA during follow-up (initial %fPSA ≥15 and positive %fPSA velocity) compared to those with "adverse" %fPSA characteristics (initial %fPSA <15 and negative %fPSA velocity). CONCLUSIONS: Diagnostic %fPSA provides no additional prognostic value when compared to other predictors already in use in AS protocols. However, %fPSA velocity during surveillance may aid in predicting the probability for future treatment change.
PURPOSE: To evaluate the utility of percentage of free serum PSA (%fPSA) as a predictor of adverse rebiopsy findings, treatment change and radical prostatectomy (RP) findings in a prospective active surveillance (AS) trial. METHODS:Patients enrolled in the global PRIAS study with baseline %fPSA available were included. Putative baseline predictors (e.g. PSA, %fPSA) of adverse rebiopsy findings were explored using logistic regression analysis. Association of variables with treatment change and RP findings over time were evaluated with Cox regression analysis. Active treatment-free survival was assessed with a Kaplan-Meier method. RESULTS: Of 3701 patients recruited to PRIAS, 939 had %fPSA measured at study entry. Four hundred and thirty-eight of them had %fPSA available after 1 year. Median follow-up was 17.2 months. First rebiopsy results were available for 595 patients and of those, 144 (24.2 %) had adverse findings. A total of 283 (30.1 %) patients discontinued surveillance, of those 181 (64.0 %) due to protocol-based reasons. Although median %fPSA values were significantly lower in patients who changed treatment, according to the multivariate regression analysis, initial %fPSA value was not predictive for treatment change or adverse rebiopsy findings. However, the probability of discontinuing AS was significantly lower in patients with "favourable" initial %fPSA characteristics and %fPSA during follow-up (initial %fPSA ≥15 and positive %fPSA velocity) compared to those with "adverse" %fPSA characteristics (initial %fPSA <15 and negative %fPSA velocity). CONCLUSIONS: Diagnostic %fPSA provides no additional prognostic value when compared to other predictors already in use in AS protocols. However, %fPSA velocity during surveillance may aid in predicting the probability for future treatment change.
Entities:
Keywords:
Active surveillance; Free prostate-specific antigen; Prostate cancer; Prostate-specific antigen
Authors: Roderick C N van den Bergh; Stijn Roemeling; Monique J Roobol; Wouter Roobol; Fritz H Schröder; Chris H Bangma Journal: Eur Urol Date: 2007-05-25 Impact factor: 20.096
Authors: Ignacio F San Francisco; Lillian Werner; Meredith M Regan; Marc B Garnick; Glenn Bubley; William C DeWolf Journal: J Urol Date: 2010-12-17 Impact factor: 7.450
Authors: W J Catalona; P C Southwick; K M Slawin; A W Partin; M K Brawer; R C Flanigan; A Patel; J P Richie; P C Walsh; P T Scardino; P H Lange; G H Gasior; K G Loveland; K R Bray Journal: Urology Date: 2000-08-01 Impact factor: 2.649
Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Hiten D Patel; Zhaoyong Feng; Patricia Landis; Bruce J Trock; Jonathan I Epstein; H Ballentine Carter Journal: J Urol Date: 2013-09-20 Impact factor: 7.450
Authors: Michael K Ng; Nicholas Van As; Karen Thomas; Ruth Woode-Amissah; Alan Horwich; Robert Huddart; Vincent Khoo; Alan Thompson; David Dearnaley; Chris Parker Journal: BJU Int Date: 2008-10-16 Impact factor: 5.588